138 results about "Host protein" patented technology

Embodiments of the invention provide methods, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Detection of HPV DNAs, genomes, and/or oncoproteins by protein chips immunological assays can be used in early clinical screening for HPV infection and general diagnosis for cervical cancer and can be advantageous performed in a multiplexed test. Comparative detection of altered levels of HPV proteins and host proteins can performed in one or more assays. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.

This invention provides a DNA sequence coding for a cleavage site which is specifically cleaved by blood coagulation Factor Xa, a vector containing such a sequence, and a host organism transformed with such a vector. Preferably, in the vector, the Factor Xa cleavage site coding sequence is fused at one end to a product and at its other end to an ATG codon or a sequence coding for at least part of a host protein. This invention also provides a process, for the production of a desired protein or peptide product in native form, comprising: transforming a host organism with a vector as described above; expressing the desired protein or peptide product as a fusion protein comprising the desired protein or peptide product fused to a Factor Xa cleavage site; and a cleaving the fusion protein with Factor Xa to yield the foreign gene product in native form.

The invention relates to a method for effectively removing a host protein in a monoclonal antibody downstream purification process. The method comprises the following steps: (1) performing deep filtration on cell culture fluid, and collecting the filtrate; (2) performing Protein A affinity chromatography on the filtrate obtained in the step (1); (3) performing virus inactivation on the sample obtained in the step (2), performing deep filtering on the sample subjected to virus inactivation, thereby effectively removing the host protein in the sample containing the monoclonal antibody. According to the method disclosed by the invention, the deep filtering after virus inactivation is adopted, the deep filtering process after Protein A affinity chromatography and virus inactivation is optimized, the content of HCP in the culture fluid supernatant collected by deep filtering can be reduced to 2.3ppm by virtue of two purification steps, namely the Protein A affinity chromatography and deep filtering after virus inactivation, and the content of the HCP can be reduced to 0.4ppm by virtue of further anion and cation exchange chromatography.

Permissiveness of human cells to replication of susceptible pathogenic human viruses is reduced by treating the cells with a selective inhibitor of prenylation of a host cell protein. Target viruses, especially Flaviviridae, are predetermined to lack a CXXX box and prenylated viral protein, and to be replication-dependent on host protein prenylation. The general method comprises (a) contacting human cells subject to infection by the virus with an effective amount of a selective inhibitor of a prenylation enzyme of the cells; and (b) confirming a resultant reduction in permissiveness of the cells to replication of the virus. Targeted enzymes include prenyl biosynthetic enzyme like HMG CoA reductase farnesyl and/or geranylgeranyl transferase enzymes.

The invention provides a method for extracting rabies virus, and is to solve the defects that great discrepancy of quality indices of different batches occurs; removal of remaining DNA becomes difficult; the protein content of the remaining host is too high; and great side effects appear clinically when the single method of molecular sieve gel chromatography is adopted for extracting rabies virus vaccine. The essential of the invention is that a hollow fiber ultrafiltration column or ultrafiltration membrane with the molecular weight cut-off of 750KD or 500KD is used to condense and partially purify harvested liquid of virus; anion exchange chromatography or molecular sieve gel chromatography is adopted to separate and purify samples; molecular sieve gel chromatography or anion exchange chromatography is adopted to separate and purify samples got in step (2). The method for extracting rabies virus has the characteristics of great productive capacity, high product quality, excellent batch stability, being remarkably effective in removal of remaining DNA and HCP, and reducing the potential safety hazard of vaccine.

The present invention relates to a purification method for recombinant human follicle-stimulating hormone (FSH), including anion-exchange chromatography, affinity chromatography, and gel filtration chromatography. The method is low in cost, few in steps, simple and feasible, and stable in quality; and no complicated denaturation and renaturation processes are comprised in the method, and the use of reversed phase chromatography, metal chelate chromatography or hydrophobic interaction chromatography, which have a greater impact on protein activity, is prevented. According to the method, firstly, anion exchange of flow-through mode is used for removing a large number of contaminating proteins, pigments and some residual DNA, endotoxin and host proteins, which not only protects the subsequent affinity filler, but also achieves a coarse purification and concentration enrichment; affinity media are conjugated with camel-sourced antibodies, the carrying capacity is high, and only an intact FSH molecule, instead of a single subunit, can be bound specifically, so degraded monomer subunits are better removed; and gel filtration can further remove residual DNA, endotoxin and host proteins, and can also remove protein aggregates and inadequately glycosylated FSH proteins.

The invention relates to a separation and purification method for a recombinant hepatitis B core antigen. The method includes the steps of thermal denaturation and clarification; ammonium sulfate precipitation; ultrafiltration and concentration, washing filtering and liquid exchange; depolymerization; first-step molecular sieve chromatography; ultrafiltration and concentration, washing filtering and liquid exchange; repolymerization; second-step chromatography. By means of the method, the high-purity, low-host-residue and high-stability recombinant hepatitis B core antigen with a uniform granular structure can be obtained, that is to say, the method has the advantages that the antigen purity is high, the residue of host protein and host nucleic acid is low, antigen particles are uniform, and industrial enlargement is easy.

The present invention relates to the identification of host cell proteins that interact with viral proteins required for virus replication, and high throughput assays to identify compounds that interfere with the specific interaction between the viral and host cell protein. Interfering compounds that inhibit viral replication can be used therapeutically to treat viral infection.

The invention is based, in part, on the Applicants' discovery of novel interactions between proteins of the influenza virus and a human host cell proteins. One of these host cell proteins, referred to herein as NPI-1, interacts with influenza virus protein NP, and may be an accessory protein required for replication of influenza virus. Another of these host cell proteins, referred to herein as NS1I-1, interacts with influenza virus protein NS₁. Compounds that interfere with the binding of the host cell and viral proteins, and inhibit viral replication can be useful for treating viral infection in vivo.

A cell-free method for translation and assembly of retroviral, particularly HIV, capsid and capsid intermediates is disclosed. Also disclosed are novel HIV capsid assembly intermediates and novel host proteins which bind to such assembly intermediates. The invention also includes a screening method for compounds that alter retrovirus capsid assembly, and a method of treating HIV using compounds which inhibit the HIV capsid assembly pathway.

The invention provides a novel affinity purification process capable of effectively lowering host cell protein (HCP) content. The affinity purification process specifically includes the steps of firstly, processing affinity filler, and performing sample loading; secondly, using a buffer solution with low pH (3.9-5.6) and an elution buffer solution 2 using sodium chloride, calcium chloride and/or arginine hydrochloric acid as additives to elute a chromatographic column; thirdly, using different pH elution buffer solutions to elute a product, and collecting the product. The affinity purificationprocess has the advantages that materials used by the affinity purification process are evident in HCP removing effect, wide in application range and widely applicable to the affinity purification process of antibody protein, and accordingly technical support is provided for the effective control of HCP content in antibody medicine.

The invention discloses a rapid purification method for recombinant pyrolytic enzyme. According to the method, escherichia coli is used as an expression host of recombinant pyrolytic enzyme, the recombinant pyrolytic enzyme is subjected to inducible expression in host cells of escherichia coli, thalli are collected centrifugally, and escherichia coli is broken by heating to release expressed pyrolytic enzyme; meanwhile, host protein of escherichia coli is denatured, devitalized and precipitated at high temperature, which is favorable for purifying pyrolytic enzyme resisting to thermal denaturation; further, high-purity pyrolytic enzyme is obtained rapidly through the process of bacteria debris catching and protein concentration of pyrolytic enzyme through ultra-filtration. The rapid purification method is easy to operate; the escherichia coli protein thermal denaturation removal rate is high; the purification concentration efficiency is high; the method is adaptable to industrial production and marketing promotion and application.

This invention provides methods for inhibiting or treating infection by viruses, in particular pox viruses by modulating a kinase, in particular by inhibiting a host cell kinase, involved in mediating viral infection. Methods to identify, validate, and classify the cellular proteins required by viruses during infection of host cells in order to select agents which can inhibit viral infection are described herein. Using a systems biology approach the virus/host cell interaction is studied from initial attachment of the incoming virus to the cell surface, to entry, transcription, replication, biosynthesis, and assembly of progeny particles. The method employs a siRNA screening platform and uses gene silencing to map the ‘viral infectome’—a compilation of cellular proteins that the virus needs to establish infection and drive the infectious cycle. Charting the infectome provides information on the viral biology by the identification of host cell proteins involved in viral infection and allows the development of novel anti-viral drugs that prevent the viruses from establishing productive infection in cells.

The invention relates to the technical field of biomedicine, in particular to a novel target resistant to Japanese encephalitis virus (JEV) infection and application. Human neuroblastoma cells (SK-N-SH) are taken as target cells, RNA technology is adopted to reduce expression of host protein of the target cells to find host factors capable of effectively inhibiting JEV-infected human neuroblastoma cells (SK-N-SH) so as to protect functions of a nerve system and prevent virus from infecting a central nerve system to cause inflammation. The invention provides application of Cofilin in preventing and treating JEV infection, and experiments find that Cofilin plays an important role in JEV-infected SK-N-SH, and JEV infection can be inhibited remarkably by reducing expression of Cofilin. The invention further provides application of Cofilin in preparing drug for preventing or treating JEV infection.

A formulation is disclosed for the treatment of diseases caused by an infectious agent which acquires host membranes protein during its life cycle. The formulation is a targeting pharmaceutical composition. It comprises a ligand capable of binding the host membrane proteins coupled to a lipid-comprising vesicle, which may comprise or not a drug effective in the treatment of the disease. Specific liposomes bearing anti-HLA-DR or anti-CD4 antibodies comprising or not antiviral drugs, namely anti-HIV drugs, are disclosed and claimed. A method of formulation as well as a method of using the formulation in the treatment of a disease are also disclosed.

The invention relates to the biomedical technology field, and provides a new target spot for resisting enterovirus 71-type infection and applications. Human colon cancer cells (Caco-2) are employed as target cells, the RNA interference technology is employed to reduce expression of the target cell host proteins, a host factor capable of inhibiting EV71 infection of human colon cancer cells (Caco-2) effectively is sought and the purpose of cutting off EV71 infection from the source (intestinal tract) effectively is achieved. Experiments show that hepatocyte growth factor-regulated tyropsine kinasesubstrate (HRS) plays an important role in inhibiting EV71 infection of Caco-2, the HRS expression is reduced, and EV71 infection can be inhibited obviously. Applications of HRS in preparation of medicines preventing or treating enterovirus 71-type infection are provided.

The invention relates to an anti-TNF-alpha monoclonal antibody chromatographic method, and belongs to the field of biotechnology. In particular, the method for removing host proteins and multimers during a process of purification of a TNF-alpha monoclonal antibody is disclosed. An ion exchange and hydrophobic composite chromatographic filler is used, a low-pH buffer solution is used for removing contaminants, and then a lower-pH elution buffer solution is used for eluting the target antibody. The method can remove a part of the multimers s and most of the host proteins, significantly improves the purity of the antibody, is cheaper in price, has no protein A falling off, is simple and convenient, has no need for adjusting the sample pH value and electric conductance, and is suitable for process amplification and industrial production.

The invention relates to a method for detecting specific recombinant human insulin escherichia coli residual host protein, which comprises the steps of taking total host protein prepared by ultrafiltration of escherichia coli fermentation liquid integrating pZRHi-1 plasmid of a human insulin gene as an antigen, stimulating a rabbit to generate an antibody, removing a human insulin antibody by affinity chromatography fixed with human insulin to prepare a specific antibody, labeling the specific antibody with horse radish peroxidase, and then detecting the residual host protein for a sample to be detected by a double antibody sandwich method. The method is high in sensitivity and specificity, and good in repeatability, and can effectively control RHI (recombinant human insulin) product quality.